Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Prostate cancer trial proving a success
Kopper with his owners
Kopper with his owners, Matt and Heather Thompson of Maryville, Tennessee.

Trial evaluates new procedure to treat prostate cancer in dogs

A clinical trial to evaluate a new procedure for treating prostate cancer in dogs is proving to be a success.

Led by Dr Bill Culp at the UC Davis Veterinary Medical Teaching Hospital, California, the trial has been performed on six dogs so far, and early results have been promising.

The treatment is similar to a procedure in human medicine that has taken hold in the past few years for treatment of non-cancerous prostate enlargement.

Known as prostatic transarterial embolization, the treatment is emerging as a minimally invasive alternative to other prostate cancer therapies.

The procedure uses MRI and CT scans to access the prostate tumour and associated blood supply. Once the blood supply is mapped, the tumour is accessed using interventional radiology techniques, utilising fluoroscopic guidance (real time "x-rays").

Catheters are placed and the blood supply to the tumour is identified. Material is then injected into the blood vessels supplying the tumour, causing a blockage and cutting off the blood supply to the tumour. The size of the gland and tumour decrease as cells die from lack of blood.

One recipient of Dr Culp's procedure is Kopper, a 14-year-old Belgian Malinois from Tennessee.

Kopper, a retired K-9 officer, was brought to the University of Tennessee's veterinary hospital last year for treament of a paralysed larynx and megaesophagus. While at the hospital, his prostate issues were discovered. Luckily the vets there were aware of Dr. Culp's clinical trial, and referred his Kopper's owners to UC Davis for the treatement.

Dr Kulp assessed Kopper's tumour using CT and MRI images which showed signs consistent with a cancerous prismatic carcinoma. The images also showed appropriate vasculature for the embolization procedure, meaning that Kopper was a good candidate for the procedure.

Together with a colleague who performs similar procedures in humans, Dr Culp successfully performed Kopper's procedure.

Kopper returned to Tennesse within a few days and, to date, his prostate has reduced in size. The hope for Kopper and all dogs undergoing this treatment, is that a decrease in tumour size will improve the qaulity and length of life for dogs with prostate cancer.

UC Davis say that the clinical trial is ongoing and the recruitment of more dogs with naturally occurring prostate cancer is needed to help evaluate the effectiveness of the treatment as an accepted standard-of-care procedure.

Image (C) UC Davis Veterinary Medicine

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.